China
· Delayed Price · Currency is CNY Jiangsu Hengrui Medicine Company Description
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide.
The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications.
It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications.
The company was founded in 1970 and is based in Lianyungang, China.
| Country | China |
| Founded | 1970 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 19,611 |
| CEO | Hong Bin Dai |
Contact Details
Address: No. 38, Huanghe Road Lianyungang, Liaoning Province 222000 China | |
| Website | hrs.com.cn |
Stock Details
| Ticker Symbol | 600276 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE0000014W7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hong Bin Dai | GM and Director |
| Jianjun Liu | Financial Director |
| Jie Ping Sun | Deputy GM and Director |
| Dr. Lian Shan Zhang Ph.D. | Deputy GM and Director |
| Dr. Ningjun Jiang M.D., Ph.D. | Deputy GM and Director |
| Xiao Han Liu | Secretary of the Board of Directors |
| Su Mei Jiang | Deputy General Manager |
| Ya Ping Shen | Deputy General Manager |
| Cheng Liao | Deputy General Manager |
| Hongsen Wang | Deputy General Manager |